Annexin Pharmaceuticals AB

Equities

ANNX

SE0009664154

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 10:54:42 2024-04-26 am EDT			5-day change	1st Jan Change
0.297 ^SEK	+2.41%		+10.00%	+14.23%

Apr. 12	Annexin Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Feb. 09	Annexin Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI

Annexin Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2023

May 17, 2023 at 02:30 am EDT

Annexin Pharmaceuticals AB (publ) reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was SEK 10.1 million compared to SEK 9.45 million a year ago. Basic loss per share from continuing operations was SEK 0.06 compared to SEK 0.07 a year ago.

Latest news about Annexin Pharmaceuticals AB

Annexin Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 12	CI
Annexin Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 09	CI
Annexin Pharmaceuticals AB Provides Update on RVO Study Confirms Promising Signals of Effect	Feb. 08	CI
Annexin Pharmaceuticals AB Announces Additional Patent Protection in the US	Nov. 14	CI
Annexin Pharmaceuticals AB Announces First Patient Treated in the Second Dose Group in RVO Study	23-10-25	CI
Annexin Pharmaceuticals AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-18	CI
Annexin Pharmaceuticals AB Announces Success in the Cancer Initiative	23-09-29	CI
Annexin Pharmaceuticals AB Announces Promising Signals of Effect in RVO- Study	23-08-11	CI
Annexin Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Annexin Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-17	CI
Annexin Pharmaceuticals AB Auditor Raises 'Going Concern' Doubt	23-04-18	CI
Annexin Reports First Imaging- Study Results in Retinal Vein Occlusion	23-04-18	CI
Annexin Pharmaceuticals Names New Finance Chief	23-03-21	MT
Annexin Pharmaceuticals AB Appoints Susanne Andersson as CFO	23-03-21	CI
Annexin Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-07	CI
Annexin Pharmaceuticals AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-07	CI
Annexin Pharmaceuticals AB Appoints Dr. Alain Thibault as Therapeutic Area Head of Oncology	23-01-18	CI
Annexin Pharmaceuticals Doses First Patient in Phase 2 Trial of Retinal Vein Occlusion Treatment	22-11-08	MT
Annexin Pharmaceuticals AB Announces First Patient Dosed in Annexin's Phase 2 Study in Retinal Vein Occlusion	22-11-08	CI
Annexin Pharmaceuticals AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-03	CI
Annexin Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-23	CI
Annexin Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-30	CI
Annexin Pharmaceuticals Wins US FDA Nod for Mid-Stage Trial of Retinal Vein Occlusion Drug Candidate	22-04-05	MT
Annexin Pharmaceuticals AB Receives Approval to Start Phase 2 Study in U.S	22-04-05	CI
Annexin Pharmaceuticals Enters Exclusive Licensing Deal For Cancer Treatment In US	22-04-04	MT

Chart Annexin Pharmaceuticals AB

Duration

Period

More charts

Company Profile

Annexin Pharmaceuticals AB (publ) is a Sweden-based biotechnology company. Its main product is ANXV, a human recombinant protein Annexin A5, for emergency treatment of patients with cardiovascular disease with blood vessel damages and inflammation. ANXV has the ability to protect and repair the blood vessels, as well as counteract the inflammation. In addition, the Company has a comprehensive patent portfolio for the treatment of diseases that occur because of damage and blood vessel inflammation. The production process is patented. The Company maintains a cell line for manufacture of Annexin A5. The Companyâs main shareholders are Mikael Loenn, Frostskog AB, Medirista AB and Colinex Capital AB.

Sector

Biotechnology & Medical Research

Calendar

2024-05-14 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ANNEXIN PHARMACEUTICALS AB	+14.23%	9.39M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs